What is Omniose?
Omniose, established in 2017, is a biotechnology firm rooted in pioneering glycoconjugation discoveries. Its scientific foundation lies in the characterization of a novel class of conjugating enzymes, developed through the collaborative efforts of scientific founders Mario Feldman and Christian Harding. Initially operating as VaxNewMo, Omniose's research operations were established at BioGenerator Accelerator Labs in St. Louis. The company has received grants from the U.S. NIAID, supporting its platform technology for the development of vaccines targeting critical pathogens such as Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae.
How much funding has Omniose raised?
Omniose has raised a total of $3.6M across 1 funding round:
Grant
$3.6M
Grant (2022): $3.6M with participation from U.S. National Institutes of Health
Key Investors in Omniose
U.S. National Institutes of Health
The U.S. National Institutes of Health (NIH) is a primary agency of the U.S. Department of Health and Human Services, responsible for conducting and supporting medical research. Their involvement suggests a strong validation of Omniose's scientific platform and its potential for public health impact.
What's next for Omniose?
The substantial enterprise-level funding and recent strategic investment indicate Omniose is poised for a significant scaling phase. This capital infusion is expected to accelerate the advancement of its vaccine development pipeline, potentially leading to critical breakthroughs in infectious disease prevention. The company's focus on a novel glycoconjugation platform suggests a strategic advantage in creating next-generation vaccines with enhanced efficacy and stability. Future developments will likely involve clinical trials and strategic partnerships to bring these innovative vaccines to market.
See full Omniose company page
